close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Regeneron Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
News headline image
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ASX REGN TLX
News headline image
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
News headline image
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today